71590-32-4

Basic information

• Product Name: N-(6-bromo-[2]naphthyl)-acetamide
• Synonyms: N-(6-bromo-[2]naphthyl)-acetamide
• CAS NO: 71590-32-4
• Molecular Weight: 264.121
• Mol File: 71590-32-4.mol

Chemical Properties

• CAS DataBase Reference: N-(6-bromo-[2]naphthyl)-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-bromo-[2]naphthyl)-acetamide(71590-32-4)
• EPA Substance Registry System: N-(6-bromo-[2]naphthyl)-acetamide(71590-32-4)

Safety Data

• Hazardous Substances Data: 71590-32-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(6-bromo-[2]naphthyl)-acetamide is used as a building block for the synthesis of complex organic molecules, which can be further developed into potential pharmaceutical compounds. Its unique structure allows for the exploration of various applications in medicinal chemistry and drug development.
Used in Agrochemical Industry:
N-(6-bromo-[2]naphthyl)-acetamide is used as a starting material for the development of new agrochemicals. Its chemical properties can be exploited to create compounds with specific pesticidal, herbicidal, or fungicidal activities, contributing to the advancement of crop protection strategies.
Used in Materials Science:
N-(6-bromo-[2]naphthyl)-acetamide is used as a component in the development of novel materials with specific properties. Its unique structure can be utilized to create materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity, for various applications in materials science.

Upstream product

• 7499-66-3 6-Bromonaphthalen-2-amine 
• 108-24-7 acetic anhydride 
• 591253-73-5 6-bromo-1-aminonaphthalene 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 71590-31-3 6-bromo-2-aminonaphthalene hydrochloride 
• 13720-04-2 1,6-dibromonaphthalen-2-amine 

Downstream Products

• 7499-66-3 6-Bromonaphthalen-2-amine 
• 855930-17-5 N-acetyl-1-nitro-6-bromonaphthalene 
• 131707-40-9 6-bromo-1-nitronaphthalen-2-amine 
• 1241377-74-1 6-bromo-naphthalene-1,2-diamine 
• 1334312-52-5 MK-8325 
• 1334314-20-3 C₄₃H₅₄N₈O₆Si 
• 1334313-80-2 C₂₉H₃₂N₆Si 
• 1334313-79-9 C₃₉H₄₈N₆O₄Si 
• 1146206-16-7 C₂₃H₂₀N₂O₄ 
• 22082-94-6 2-bromo-6-phenylnaphthalene 
• 116668-47-4 6-amino-2-naphthoic acid 

Relevant articles and documents

Industrial preparation method of 6-bromonaphthalene-1, 2-diamine

The invention discloses an industrial preparation method of 6-bromonaphthalene-1, 2-diamine. The method comprises the following steps of: S1, making a compound III react with acetic anhydride in the presence of alkali and a catalyst to obtain a compound IV; S2, in the presence of acetic anhydride and nitric acid, taking acetic acid as a reaction solvent, performing reacting and purifying on the compound IV obtained in the step S1 to generate a compound V; S3, adding the compound V obtained in the above step into a solvent for dissolving the compound V, then adding a metal reducing agent and an ammonium chloride solution, heating to carry out a reaction for 6h, performing centrifugal filtering after finishing the reaction to obtain a filtrate, washing the filtrate with a sodium chloride solution, and performing concentrating to obtain a compound VI; and S4, adding the compound VI obtained in the previous step into a methanol solution, dropwise adding strong acid, replacing the solvent after finishing the reaction, performing crystallizing and filtering to obtain a compound 8. According to the method, the process is optimized, large-scale production can be achieved, applied materials are all commercial reagents, the cost is reduced, and the operation convenience is improved.

Discovery of potent macrocyclic HCV NS5A inhibitors

HCV NS5A inhibitors have demonstrated impressive in vitro virologic profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed-dose combination (FDC) regimen for the treatment of HCV infection. Merck's effort in this area identified MK-4882 and MK-8325 as early development leads. Herein, we describe the discovery of potent macrocyclic NS5A inhibitors bearing the MK-8325 or MK-4882 core structure.

COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS AND PHARMACEUTICAL USES THEREOF

The invention provides compounds as hepatitis C virus inhibitors and pharmaceutical uses thereof. Specifically, the invention provides compounds of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel fused tricyclic compounds, compositions comprising at least one fused tricyclic compound, and methods of using fused tricyclic compounds for treating or preventing a viral infection or a virus-related disorder in a patient.

FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.

Discovery of novel Tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats

Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were di

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.